Aberrant RNA splicing caused by variant in DEPDC5 identified in a patient with pharmacoresistant epilepsy
Neurogenetics · 16.03.2026 · 27 (1)
DOI: 10.1007/s10048-026-00890-7 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neurogenetics, online erschienen am 16.03.2026. Verfasst von Cong Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics/Prenatal Diagnostic Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, China. Hauptthemen laut MEDLINE: RNA Splicing, GTPase-Activating Proteins, Drug Resistant Epilepsy, Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Familial focal epilepsy with variable foci-1 (FFEVF1) is an autosomal dominant form of epilepsy. The phenotypic spectrum of FFEVF1 is wide, with incomplete penetrance. Therefore, making a definite diagnosis based solely on the phenotype of patients is challenging. We report a 6-year-old female patient presenting with epilepsy, global developmental delay, coarctation of the aortic arch, and neuronal migration disorder. Trio whole-exome sequencing as well as Sanger sequencing were conducted to identify familial epilepsy-associated variants in the family. The pathogenicity of the variant was confirmed through mRNA splicing analysis in vivo and in vitro. Genetic testing identified a heterozygous variant, c.2633 + 2T > C, in the DEPDC5 gene. The pathogenicity of this variant was substantiated through in vivo and in vitro mRNA splicing analyses. These studies demonstrated that the variant induces multiple aberrant splicing events, all resulting in reading frame alterations. Consequently, the variant was classified as Likely Pathogenic according to ACMG guidelines. This study establishes a genetic diagnosis for the patient’s pharmacoresistant epilepsy, facilitating precise genetic counseling. Furthermore, a definitive diagnosis aids in reproductive risk assessment and supports future pre-implantation or prenatal testing for the family. Finally, this novel c.2633 + 2T > C variant expands the known mutational spectrum of DEPDC5.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics/Prenatal Diagnostic Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, 610041, China.
- Department of Medical Genetics/Prenatal Diagnostic Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, China. hhwj_123@163.com.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, 610041, China. hhwj_123@163.com.
Zitieren
APA
Zhou, C., Wei, X., Xiang, Q., Mai, J., & Wang, J. (2026). Aberrant RNA splicing caused by variant in DEPDC5 identified in a patient with pharmacoresistant epilepsy. Neurogenetics, 27(1). https://doi.org/10.1007/s10048-026-00890-7
Vancouver
Zhou C, Wei X, Xiang Q, Mai J, Wang J. Aberrant RNA splicing caused by variant in DEPDC5 identified in a patient with pharmacoresistant epilepsy. Neurogenetics. 2026;27(1). doi:10.1007/s10048-026-00890-7
BibTeX
@article{Zhou2026,
author = {Zhou, Cong and Wei, Xing and Xiang, Qinqin and Mai, Jingqun and Wang, Jing},
title = {Aberrant RNA splicing caused by variant in DEPDC5 identified in a patient with pharmacoresistant epilepsy},
journal = {Neurogenetics},
year = {2026},
volume = {27},
number = {1},
doi = {10.1007/s10048-026-00890-7}
}
EUVIMED